Craig Lindsley received the PhD degree in chemistry from the University of California, Santa Barbara, in 1996 and pursued postdoctoral studies in the Department of Chemistry at Harvard University.

After brief stints in the Medicinal Chemistry Departments at Parke-Davis and Eli Lilly, Dr. Lindsley moved to Merck and Company to establish and lead the Technology Enabled Synthesis Group within the Medicinal Chemistry Department at Merck’s site in West Point, PA. During his six years at Merck, Dr. Lindsley delivered six preclinical development candidates for cancer and neuroscience programs.

Dr. Lindsley moved to Vanderbilt University in 2006 to direct the medicinal chemistry efforts of the Vanderbilt Program in Drug Discovery, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. Dr. Lindsley is Associate Editor of Current Topics in Medicinal Chemistry and serves on the editorial boards of two other international journals. He serves on the Scientific Advisory Board of the NIH National Chemical Genomics Center, and is a worldwide medicinal chemistry consultant for Amgen. Dr. Lindsley’s current research is focused on development of novel treatment strategies for schizophrenia, Parkinson’s disease, and other brain disorders.